Can a 'Baby' dose of hormone drugs prevent breast cancer without side effects?

NCT ID NCT07499999

First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 3 times

Summary

This study compares two low-dose hormone drugs, exemestane and tamoxifen, in 140 postmenopausal women at high risk for breast cancer. The goal is to see which drug better maintains quality of life while reducing cancer risk. Participants will take the assigned drug for 12 months, and researchers will measure menopausal symptoms and hormone levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.